Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Look at the BioMed website. Look at the PPS of the companies BioMed alerted 2 days previous to the alert. Look at the run up over the next 1-3 days. Look at the big drop/correction after the run ended. Look at the slow bleed back to pre-alert price range if the company didn't issue any material PR's.
IMO, BioMed reports is a trading tool and shouldn't be confused a provider of decent DD. They do have an FDA calendar which is useful, but it's the alerts aspect of BioMed that drives stock prices.
What's more disconcerting is the evidence that BioMed alerts actually leaks their alerts before they are emailed to paid subscribers. I've seen 20-50% rises in PPS on the 1-2 days before getting the alert (I'm a paid subscriber), which strongly suggests that quite a few people are in the know before subscribers.
To reiterate, I'm long here and have held shares closely since .069
I was disappointed that there was no hard news which caused this price spike, as some tangible company event would provide much more support to a PPS rise than an alert from BioMed IMO.
They have their role to play and they disclose. Pull up a comparison of the stocks they alert and you'll see a very similar and distinct pattern: the spike on high volume followed by the rug being pulled out from under the newbie bag holders.
Check out PARD, NWCI, PDMI, MCLN to name but a few.
BioMed Reports is a business that, like all other businesses, needs to make money. They wouldn't make money without issuing "alerts" on a regular basis. Does that mean that these "alerts" are valid and offer material insight into the companies they follow? I guess tha's what each investor needs to decide.
It's ironic that they mention Vermillion every time they cover a diagnostic stock considering that, like most of the world, BioMed completely missed the Vermillion ride.
BioMed reports posted an alert about HDVY for members only on Friday AM. I assume the world will get the alert over the weekend. Certainly explains the spike and the volume.
As usual, the report is incomplete and laced with hyperbolic pump oil- they trot out the comparison with Vermillion.... and there's the BioMed blue light special: the rumor of "big news" on the horizon.
As a long, I'll hold no matter what the PPS does on Monday, but given BioMed's influence on other stocks I follow, don't be surprised to see a large pullback once the traders start bailing out.
"Hard evidence" about this transaction is very hard to come by.
FWIW, I'd be more interested in the details of the 53% increase- how much, how long, and what for- than knowing whether it was DR or the current BOD who pulled the trigger.
While they happily PR'ed the insider 4 buys and the company's hopes and dreams for the future, I'd prefer a bit more transparency around material events.
IMO sneaking in 25 million shares with no PR, no mention of the offer's PPS or holding time and the term "shareholder friendly" don't quite fit in the same company profile.
This latest offering was a serious increase in the OS. Issuing those shares with no genuine explanation and no commitment to return to a fully reporting BB status is quite typical of a Pink Sheet outfit.
lol, I put 44,000 up for sale at .02 and no one wanted them. We're well and truly STUCK>
Good point. Any DD would have shown that Barnhill has never been a communicator when it comes to shareholders.
He has, however, been extremely successful in this field. His record speaks for itself.
BTW, pretty much all my penny stocks have taken BIG hits lately.
Quest wants the test. They'll make tons of $$ marking it up and reselling it to doctors worldwide. It's simply a question of "does the test work significantly better than the PSA?"
Wow, that's a bit rough Gamgood. While I never deified DR the way some here idolized him at every turn, I could see his game plan and I concurred with it. Like DR, I thought getting FDA approval would be enough- LTC would sell itself because of the amazing contrast with current suturing technologies.
That said, the deals he cut did indeed suck....except for Empire....which IPO never happened. But Cornell, Banco, La Jolla.....hard to justify those deals IMO. He owned tons here....more than the new guy ever will I believe, and he guarded those shares like few CEOs on the OTC or any exchange. But it's a bottom line assessment that a business is judged by, and on that account, well, we all know the current PPS
I hope you're right. It's a big adjustment, the paradigm shift from DR keeping the O/S low and paying the bills out of pocket to the quick issuance of 25 million new shares.
I am a bit confused: if you were a money lender thinking about a slice of the LTC pie, wouldn't you want the trip to the Ukraine for a look/see before you ponied up the money? Why accept 25 million shares and then go to the Ukraine to see what you've invested in?
3 answers come to mind:
1. The 25 million shares are but a down payment on the $$ that CTGI hopes to raise from this investor. In essence, the 25 million shares at an unknown price (to us) are what CTGI has to pay just to be taken seriously. Last I knew, the A/S here was 100 million shares, so as we currently stand, there's a limit to the money that CTGI can raise through dilution. (preferred notwithstanding)
2. The actual PPS of the offering is so much lower than the current PPS that the investing company decided it was worth the risk. Other lenders in the past have had great success making money from CTGI even as the company has floundered.
3. Everything is fine and the fact that we have a pink sheet company that is not obliged to disclose details or material events (except when insiders buy shares) is just paranoia on my part.
Other questions worth discussing:
1. How much does it cost to roll out a medical device like LTC? (advertising, production, trade show attendance, luminary sites, employee wages, PR, etc)?
2. How much does the company currently owe? The BOD made it clear in the last PR that one reason they wanted to raise money was to take care of debts.
It's a busy time. Looking back at the time when we all wished we had sold for better than $2 a share, it's a shame the company itself didn't sell shares then. Our collective holdings are a pittance compared to the 25 million that just walked out the door.
I was hoping for Nov 2009, based on the company's original time line for the different phases of development. Any date now is pure conjecture unless it comes from the company itself.
IMO, this is a terrible stock for short term trading- there's warrants aplenty out there and the volume hasn't been consistent enough to make sound decisions based on TA.
I'll know the day they release news of the test by looking at the $$ in my portfolio. On that day I'll be very pleased that I held my shares.
Also IMO, once the urine test launches, there won't be as much "wait and see" with the breast cancer test currently in development.
And as a sweetener, they hired someone last year to use their proprietary technology to make some dough from applications other than med testing.
Low overhead, few employees, established margins.
Doesn't matter. It's a simple question with HDVY: will the urine test be successful? If you think "yes", (as I do) any price in the 52 week range is a gift. If you think "no" WTF are you doing here, lol?
Any time I get worried, I look at the BOD page and their accomplishments to date. These guys get shizz done. And when the urine test is successful, the breast cancer test will have a lot more cred going forward.
How much money do you think that good chunk actually is? Most decent companies would PR the share offer with a price.
morning. still looking good on those ECSC plays
lol, don't confuse politeness with general opinion, lowman.
Since you evaded my question, I'll be more to the point: on a previous occasion you posted details of a phone call to management and in the same post made some pretty major claims that were nothing more than personal conjecture. Seeing the call and the claims linked required very little imagination, which prompted me to ask if that was indeed the case. Then, like now, you refused to answer the question directly. So be it.
I take calls to management seriously. When I had talked to DR in the past, I posted what I heard in the call, as opposed to what I wanted to hear.
I value every posters' opinion on this board. However, I find it ethically dubious at best to not clearly delineate between what was said in a phone call to management and a poster's own ideas.
Agreed. I'm holding my shares here....but let's face it, we're stuck. To bail now, you'd be giving away 50% of the current PPS to the MM's.
Look at it as enforced discipline: you will learn patience, grasshopper, and you will be rewarded for it in the end.
I'll chuck a stink bid in tomorrow just in case someone really needs that.023 for lunch money.
Thanks ypsiCPA for the update. Why was ypsiCPA's original post, #31033 deleted?
lowman, could you please clarify Dr Kutz's travel plans: when you called management, who did you speak to? And were you told Dr Kutz was definitely going to the Ukraine? If not, is your "belief" based on anything beyond the last PR?
TIA
Ah, a week with the yellow jersey....even a blind squirrel......I'd like to use my freeze on the entire competition now!!!!
Cheers from Australia
Very nice. And imagine all of it wireless and available as a mobile application. This company is really pioneering the future of medicine: fewer doctors visits, patient controlled devices linked to a doctor's database, WIRELESS!
Should be an active week ahead for NWCI
Thanks for the heads up on NWCI.OB
The party's just starting here. Once you read through the amazing resumes of the BODs and the officers, you get to the meat and potatoes:
From the website:
Building on positive industry attention to cardiac safety and our increasingly robust clinical validation, we officially launched QTinno in August. QTinno provides an automated analysis of cardiac safety in drug development. This launch was enabled by an extensive effort by us to ensure organizational readiness to effectively support the sale, implementation and support of QTinno. As many of our shareholders know, every drug in development must undergo a TQT study to determine cardiac toxicity, and currently these studies involve manual or semi-automated readings by cardiologists.. We believe QTinno will replace this primarily manual process with a fully automated solution which promises higher quality results and a more efficient approach.
With our lead product launched, we continue to make steady progress toward securing revenue-generating studies. Notable commercialization-related achievements include:
* A top-five pharmaceutical company named QTinno as the technology that will be used in all of its fully automated TQT studies. This pharmaceutical company evaluated several automated cardiac safety solutions before choosing QTinno.
* A Master Services Agreement (MSA) was signed with a top-three Clinical Research Organization (CRO), which will use QTinno as their technology in fully automated Phase I TQT studies delivered by their centralized ECG core lab. We expect to collaborate on the first fully automated study in the near future and anticipate the customer will increasingly deliver fully automated studies with QTinno.
* Another top-five CRO also signed an MSA with us, licensing QTinno in all TQT studies where fully automated readings are obtained. QTinno will enable them to eliminate the need to utilize ECG core labs for TQT studies delivered by their Phase I units. Ultimately, QTinno will provide the CRO with incremental revenue opportunities by capturing fees that were previously outsourced to ECG core labs.
* Dedicated Phase I, an innovative provider of clinical research services signed an MSA with us, licensing our QTinno software solution in all TQT studies where fully automated readings are obtained.
With Qtinno, the company has pulled the ladder up behind them IMO. They have stormed the market with the new benchmark for monitoring cardiac safety, which all companies proposing new drugs will need to utilize. The low float is the added sweetener here. It's easy to see why the company is a likely candidate for a buyout, and why, even after the nice run-up in the PPS, today's closing price is just the beginning.
Joe, question on ADAT. Since the deal with the 1.00 warrants was announced, the PPS channeled between 1.00 and 1.17
Are you holding? Do you think the short warrant time is a reflection of
1. good things happening in the 90 day time frame
2. good things happening soon after after the 90 day time frame, hence why ADAT wants a decision before the 90 days are up.
Long 8,600 at 1.03 and thinking about rotating some cash out to other plays
TIA
P2O is the whole story here. If/when 3rd party verification confirms John's forecasts, the sky's the limit; imagine the value of converting waste plastic, an environmentalists holy grail and a stand alone technology that has nothing resembling competition anywhere in sight. The growth potential here rivals that of the microchip.
Like most here, I'm in total agreement of your assessment of JB's character. FWIW, in addition to building an amazing and unique company, JB is re-defining the role of a CEO for 21rst century biz: no more, back room deals, no more waiting for information vaguely distributed by IR machines and no more BS glossy prospectus brochures/company reports that clog your mailbox 4 times a year.
We have instant communication capabilities now. CEO's who take advantage of this technology will be the ones who are up-front, transparent and completely knowledgeable about their companies. They will be the ones who speak candidly because their companies support a vision for a better world that most corporations today could give a flying eff about.
CCTI looks good in the mid term. With LTC, I'll do my part by ringing Dr Kutz's practice in late Jan to see if "the doctor is in". I hope he isn't!!
Honestly, the talk of ISRG being involved here isn't at all helpful IMO. ISRG, J&J and anyone else in big pharm have departments of emerging technology scouring the medical world for the cure for cancer. They're not in the dark on LTC. They are more than likely in the know.
Going back to 2008, we know now that there was no deal contingent on FDA approval and today's BOD letter strongly suggests that, no, there isn't a partner with deep pockets in the wings. On the contrary, the company finds itself in the familiar position of having to raise money to stay visible. This is what they themselves state in the letter. The big difference now is that there's no more tapping DR's amazingly generous pockets to keep the lights on and the wolves at bay.
The BOD seems to make it pretty clear that nobody is beating down the CTGI doors to have a JV interest in LTC. Hiring a management company is quite a different matter than forming a partnership...at least the kind of partnership we all hoped LTC would attract...the one where we supply the amazing technology and the partner supplies the coin. The question is why aren't there any takers for LTC? We had Frank D and Richard A peddling LTC before it was approved.....
I looked at the LTC website. An extract of the old Gyrus/LTC comparison follows:
Conclusion
• The LTC system produces consistent and reliable seals.
• Both systems met the performance criteria of holding a
pressure of approximately 350 mm of Hg for a period of 10
seconds.
• The seal burst pressures made with the two system were
statistically equivalent, although the LTC system seal
pressures were slightly higher.
• The LTC system produces seals with virtually no tissue
sticking to the forceps while the Gyrus system produced a
slight amount of sticking.
• The automated LTC system employs a unique output that
controls the tissue temperature to a narrow range,
effectively minimizing damage to normal tissue and
preventing over-desiccation and charring in the seal itself.
• The LTC system produced significantly less lateral thermal
spread from the edge of the jaw than the Gyrus system.
Is LTC a better mousetrap? For sure. Is it, in its current FDA approved state, that much better? Even the study suggests not. The real value in LTC is its unique ability to suture lungs, livers, pancreases, etc. Until that application of LTC is proven and approved, we better hope CCTI has some serious punch.
Finally some news. And no real surprises on the LTC front. No partner in sight....so I agree that the selling is a result of the ambiguity of the future of LTC....and Allison chipping away at his 100k a month.
In essence, the BOD has stated their intent to commercialize LTC on their own. Like it or not, the costs involved in rolling out a new technology like LTC are well beyond the company's current financial means. On what terms will Empire (or anyone) front CTGI what amounts to 10's of millions of dollars (rough guess) to start up the biz? Will the current board be as frugal with issuing new shares as DR was? Then again, a low O/S with no progress isn't a very happy outcome either.
Remember, there are huge costs in PR, production, and demonstrating LTC at conferences and in hospital. It's hard to believe that a huge med company wouldn't jump at the chance to control a chunk of LTC if the reports from the Ukraine are all true.
CCTI looks more promising. Hopefully it will play a role similar to LTC when the C02 separator was supposed to drive the company ahead financially and pave the way for FDA approval of LTC.
What a long, strange trip it's been!
Wow lowman, first it was the "whiners" who did in DR, now it's the shear joy (holidays and all, combined) that his ticker just couldn't take the overwhelming nature of finally being 'revenue producing'
Let the man RIP for goodness sake. Some things we'll never know. What matters now is ahead of us. I emailed Dr Kutz to ask him if he used LTC in his work as a surgeon. What better recommendation for the company?
We need some giddy-up here. Somehow, CTGI needs the ability, like most other upstart companies, to "give away" some LTC in order to create a market. How much would it cost to install LTC at, say, Dr Kutz's clinic or a local hospital he has connections with?
From the Louisville Magazine. Note the 2007 date ninja. Maybe you should give rocket science a rest and concentrate on simple DD. lol. But seriously, better to give the personal attacks a rest and simply disagree. We all want the same thing here. We all have different opinions about how to get it. We've all been wrong in the past or we all wouldn't currently be sitting on shares worth 1/15 of their one time value.
HAND CHOSEN
By Joe Atkinson
August 2007
Photos By Patrick Pfister
... eventually ends with Kleinert settling instead for an ice water. He then pulls a wad of trash from his pocket, and begins playfully eyeing the trash can 20 feet away. “I’ll give you $5 if you make that,” says Bill Sandbach, chief executive officer of KleinertKutzHandCareCenter, the same man who offered Kleinert a drink earlier.
The doctor doesn’t respond; he simply smiles to himself, and drains the shot.
He’s used to hitting the mark. Kleinert, 85, and his partner, Dr. Joseph Kutz, 79, have spent the better part of 50 years revolutionizing hand surgery.
As an interim (per lowman) CEO, Kutz is a splendid choice for the purposes of continuity and enhancement of CSMG/LTC image recognition.
Yup. I agree. key word being interim as lowman remarked in a previous post. Until his suggestion of the possibility of a caretaker CEO, there were only posts about what a great choice Kutz is. Now in your post, I read the word "interim" with a nifty disclaimer in parenthesis. LMFAO
Warren Buffett turns 80 in 2010, and he does better in his profession than any man half his age or any other age.
"By 1963, Warren Buffet and his associates were the largest stockholders and Buffett began to take a more active interest in the company."
Let's see...2010-1963= 47.....80-47= 33. Thanks for illustrating my point ninja.
This isn't about Kutz's professional reputation, which is indeed illustrious. It's about the right man for the job at this particular time. As a handover guy, Kutz is fine, but longer term, IMO, the company needs a full time shaker and mover to wow the world with its technologies. If you think Kutz is the man for the job (interim? lol), thanks for your input. If you find my input shabby and offensive, you know what button to push.
Lowman, I hope you're right about a new CEO coming on board real soon....cause it's gonna happen one way or another. Kutz is, I believe, 81 years old. he's not what the company needs today.
And before I get jumped on for being guilty of age discrimination, let's get serious about the amount of time and energy any young company needs to get off its feet. If there's much time to be spent sifting through the files that DR left behind and grooming the relationships he pioneered in the Ukraine, it's ludicrous to give the task to someone that old: to be brutally frank (no pun intended) how damaging would it be for CTGI to have to name a second CEO in a short time span of, say, six months to a year?
Nope, what CTGI needs now is a mid-40's to 50's MBA-holding-salesperson with experience in acquisitions and mergers. I for one am not too optimistic about our future with an 80 year old academic at the helm.
a side issue: what financial in their rightful mind would advise DR's heirs to not diversify his CTGI holdings when the estate is settled. And yes, I know Esmeralda was a member of the BOD.
I hope you're right about the acquistion, but another plausible theory is that they are doing website maintenance and want the site down when there won't be much traffic.
With the JBII comparison, the OS is the only comparable IMO. JBII promises a plastic to oil technology, which if proven up, will result in limitless revenues and franchises. I'm in for 2800 shares at 1.17 and won't sell a share until P2O is proven or dis proven. The JBII CEO is in a league of his own; the amount of disclosure and information that he has released is another stark contrast in the way JBII and SPHE do business.
SPHE has contracts that have dates and deadlines. At this point, their success depends on the growth of the IT needs of the Canadian government and SPHE's ability to successfully bid on those needs.
Looking at SPHE on its own merits, I'll be adding at anything under .03 if it dips that low. The OS is fantastic, the CEO has a lot of skin in the game and the odds of it hitting .10 are much greater than most potential 2 1/2 baggers that I currently follow.
A sad, sad day indeed. DR's work and dedication for CTGI were unparalleled, his belief in the company unfaltering. Condolences to all his family and friends.
If the merger is anythng like SPHE's quiet period, it's gonna' be one helluva' merger, lol
It would also behoove the company to get those financials audited if they want serious attention from big players.
Financials out...same old story: no revs but at least the OS stays the same at 52 million. Yawn.
Bust out the '09 financials, then this will trade much, much higher if 2008 is an indication. One thing SPHE management can't be accused of is issuing pump PR's.....or any PR's for that matter, lol. It's that lack of company lube that will keep this stock out of the hands of pumpers and day traders.
Back in August I was a lot more impatient here, but IMO the bad news was all cooked into the autumn PR. We've turned the corner. At this price, you can still buy in for 20% under what the SPHE creditors were willing to accept. It might not be the most glamorous 20% available on the market today, but it's there for the taking.
I added at the opening yesterday and will continue to do so if this stays under the radar through the end of the year.
Anyone care to elaborate on the difference between "operating profit" and "net profit"?
ADAT 1.01
http://www.thestreet.com/_yahoo/story/10644200/1/authentidate-big-bet-on-a-small-company.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA
Check out the PR: 3.4 million shares sold in a PP at 1.00 per share.
Warrants to buy another 3.4 million shares at 1.00.
Warrants expire in 90 quick days
Stock closed yesterday at 1.01
3.4 million $$ is quite a bet on some short term news of serious consequence
Well done researcher on the excellent picks! And thanks Hank for putting the roast beef on the table again!
Lots of assumptions here with no financials to back them up. Without knowing margins, we have no idea what SPHE is pocketing from these contracts. Without forward guidance, we can't begin to estimate their bidding strategy on these contracts.
We do know that SPHE was given a lease on financial life last Q by their creditors. The forbearance on interest repayments was valued at .05 a share....still a nice premium to today's closing price.
My pain here is 65000 shares at an average of .073. IMO, the last Q cooked in a lot of bad mojo- lawsuits, debt.....I'm hoping they divulged the worst of it and can now show strong signs of a turnaround.